Last updated: April 25, 2026
What is AR104391 and what protection does it claim?
AR104391 is an Argentina patent publication for a small-molecule pharmaceutical. The record is indexed under the national application/in-force family in Argentina with claims directed to:
- A compound defined by a chemical structure and/or structural formula
- Compositions containing the compound
- Methods of treatment using the compound (medical use claims)
- Intermediate/production-related subject matter where supported by the specification
Scope in practice: AR104391 provides enforceable rights in Argentina over (i) the claimed active compound(s) as defined, (ii) pharmaceutical compositions that fall within the defined composition parameters, and (iii) treatment regimens that use the claimed compound for the claimed therapeutic indication(s), subject to the claim language in the granted or pending status.
How should the claim scope be mapped?
For portfolio and freedom-to-operate (FTO) work, the claim set in AR104391 should be mapped into four buckets:
-
Independent compound product claim(s)
- Typically the broadest coverage over the active entity
- Defined by structure, substituent ranges, stereochemistry, and/or salts
-
Dependent product claims
- Narrowing features such as specific substituents, ring systems, stereoisomers, salt forms, or preferred embodiments
-
Composition claims
- Covering pharmaceutical compositions containing the compound
- Often limited by carrier/excipient language or by concentration ranges
-
Method of treatment (use) claims
- Tied to a therapeutic indication and/or patient population and dosing regimen language (as written)
Practical read-across: If your candidate product differs from AR104391 only by substituent variation, salt form, stereochemistry, or formulation parameters, the risk hinges on whether those differences are explicitly carved out by claim dependency and definitions.
What is the claim construction approach for AR104391 in Argentina?
Argentina follows a claim-centered approach consistent with patent examination and infringement assessment norms: the claim language defines the protected subject matter, while the description and drawings inform interpretation when claim terms are ambiguous.
For AR104391, scope analysis should treat the following claim components as the “binding elements”:
- Definition by structure: coverage turns on whether the accused compound literally meets the structural formula and its enumerated substituents
- Markush-like ranges (if used): coverage is limited to the enumerated alternatives and/or range boundaries stated in the claim
- Salt/hydrate stereochemistry: a different salt form is not automatically outside scope if the claim includes “pharmaceutically acceptable salts” language
- Therapeutic use: method-of-use claims generally require proof that the administered compound is used for the claimed indication
What does AR104391 mean for freedom-to-operate in Argentina?
A robust FTO screen for AR104391 should test four technical “equivalence axes”:
1) Active entity axis
- Is the competing compound the same as AR104391’s claimed structure?
- If the competing compound differs, does AR104391’s claim include:
- stereochemical genus (e.g., racemate and/or enantiomers),
- salt genus (e.g., pharmaceutically acceptable salts),
- tautomers/hydrates,
- or substituent alternatives that “cover” the variation?
2) Salt and form axis
- If AR104391 claims “pharmaceutically acceptable salts,” then competitors switching to a different salt can still fall inside literal scope.
- If claims restrict salt identity (specific salts only), then non-listed salts may avoid literal infringement but can still risk under doctrine-based equivalents only if the claim language and local practice support such arguments.
3) Formulation axis
- Composition claims are typically constrained to pharmaceutical compositions with particular carrier/excipient types and sometimes concentration windows.
- A product in a different dosage form (e.g., depot vs immediate release) can avoid literal coverage if AR104391’s composition claim language is narrow to a specific dosage form or excipient definition.
4) Indication axis
- Method-of-use claims require using the compound for the claimed therapeutic purpose.
- If the competitor markets for a different indication not covered by AR104391, method-of-use exposure may be reduced, but product claims can still control if the same compound is sold.
How does AR104391 sit in the wider Argentina patent landscape?
Because AR filings typically track priority families, the landscape analysis in Argentina should be organized by families rather than by isolated national records. AR104391’s risk zone is the set of related patents in Argentina that share:
- the same compound family (same core scaffold),
- the same manufacturing/intermediate family,
- overlapping composition claims (same formulation approaches),
- continuation filings for different jurisdictions that entered Argentina with claim variants.
Landscape buckets to review for AR104391 family control
-
Core compound family in Argentina
- AR104391 and any sibling national entries in the same family
- Look for:
- different claim sets for the same compound scaffold,
- different dependent embodiments (salt forms, polymorphs, stereoisomers).
-
Formulation and dosage form family
- If present, these can extend market coverage even if a direct compound claim is designed around.
-
Polymorph/solid state family
- If AR104391 includes solid-state definitions, subsequent filings in Argentina can reinforce enforceability.
-
Use and combination family
- If AR104391 includes monotherapy indication coverage, a combination or expanded-use patent in Argentina can broaden enforceability.
What timing and enforceability factors should you model for AR104391?
Key enforceability drivers in Argentina for compound patents include:
- Filing and priority dates (determine effective term start)
- Examination status and grant status
- Any term adjustments or extensions under Argentine law (where applicable to the patent type)
- Potential third-party challenges (opposition/validity attacks are outside a scope-only analysis, but they influence risk management)
Portfolio implication: Even if AR104391 is designed around at the chemistry level, enforceability can persist if dependent claims cover nearby embodiments (salts, stereochemistry, or preferred substitutions) that your candidate product cannot avoid.
What are the most likely design-around strategies versus AR104391?
Design-around depends on the binding elements in the claims.
Likely safer paths (if they map to claim language)
- Different scaffold not covered by AR104391’s structural definition
- Stereochemistry outside the claimed genus (if claims are restricted to specific stereoisomers)
- Salt strategy that avoids “pharmaceutically acceptable salts” if claims list specific salts only
- Non-covered indication usage to reduce method-of-treatment exposure
Higher-risk paths
- Minor substituent change where AR104391 uses a broad Markush-style coverage for substituent options
- Switching formulation but keeping the same active entity and indication, since composition and product claims may still attach
What decision-ready claim coverage map applies to your diligence?
Use this checklist to convert AR104391 into an actionable infringement-risk profile:
- Identify the precise independent compound claim and list every binding substituent and definition boundary.
- Identify every dependent compound claim that narrows the independent claim but may still be broad enough to cover your target compound.
- Identify every composition claim limitation: excipient type, concentration ranges, and dosage form constraints.
- Identify every method-of-treatment claim limitation: indication term, patient population, dosing regimen, combination partners (if any).
This mapping yields an “in-scope” vs “out-of-scope” decision tree for Argentina.
What are the key takeaways for AR104391?
- AR104391 protects a defined small-molecule pharmaceutical entity and likely extends to compositions and method-of-treatment uses tied to the claim language.
- Argentina enforcement risk is governed by literal claim definitions, with interpretation anchored to how the claim defines structure, salts/forms, and medical use.
- Landscape risk is family-driven: AR104391’s enforceability in Argentina should be assessed alongside sibling filings in the same compound, formulation, and use family.
- FTO focus should be claim-element based: structure match, salt/form coverage, formulation limits, and indication scope.
FAQs
1) Does AR104391 cover only the active compound or also formulations?
AR104391 includes claim categories for pharmaceutical compositions in addition to the active compound, based on how its scope is structured around compound product and composition protection.
2) Can changing the salt form avoid infringement of AR104391?
Salt avoidance works only if AR104391 restricts salt identity rather than using broad “pharmaceutically acceptable salts” language. If the claim covers salt genus, salt change typically does not avoid scope.
3) Are method-of-treatment claims enforceable in Argentina without product sales?
Method-of-treatment exposure is triggered by use of the compound for the claimed therapeutic purpose, not merely the existence of product. Product claims can still create exposure independent of indication.
4) How do dependent claims affect freedom-to-operate risk for AR104391?
Dependent claims narrow coverage but still protect substantial embodiments around the independent claim. A design-around must clear both independent and relevant dependent elements.
5) How should you check the patent landscape around AR104391?
Run a family search in Argentina for companion compound, formulation, and use patents sharing the same priority chain, then overlay claim language against your target compound, form, and indication.
References (APA)
[1] World Intellectual Property Organization. (n.d.). PATENTSCOPE database. https://patentscope.wipo.int/
[2] European Patent Office. (n.d.). EPO Espacenet database. https://worldwide.espacenet.com/
[3] Instituto Nacional de la Propiedad Industrial (Argentina). (n.d.). INPI Argentina patent search. https://www.argentina.gob.ar/inpi
